CN Patent

CN106456640B — 色瑞替尼制剂

Assigned to Novartis AG · Expires 2021-05-14 · 5y expired

What this patent protects

本公开是关于一种包含色瑞替尼(Ceritinib)的新型药物组合物。特别地，本文涉及通过湿法制粒所制备的片剂，其中使用聚维酮作为黏合剂。所述组合物的另一特征是所述药物及所述黏合剂形成内相，而所有其他赋形剂是以粉末形式作为外相添加。这样可防止组合物的粘冲并可达到足够的片剂硬度。

USPTO Abstract

本公开是关于一种包含色瑞替尼(Ceritinib)的新型药物组合物。特别地，本文涉及通过湿法制粒所制备的片剂，其中使用聚维酮作为黏合剂。所述组合物的另一特征是所述药物及所述黏合剂形成内相，而所有其他赋形剂是以粉末形式作为外相添加。这样可防止组合物的粘冲并可达到足够的片剂硬度。

Drugs covered by this patent

Patent Metadata

Patent number
CN106456640B
Jurisdiction
CN
Classification
—
Expires
2021-05-14
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.